Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celltrion’s Biosimilar Rituximab First In Line For FDA Review

Executive Summary

After launching its biosimilar infliximab Inflectra in the US late last year, Celltrion is targeting a leading position in oncology in the US with its biosimilar rituximab emerging as the first to be accepted for review by the US FDA.

Advertisement

Related Content

Deal Watch: Boehringer's Busy End Of Year Includes Deals With Roche, Autifony
Korea 2017 Review: Biosimilar Advances, R&D Progress Restore Confidence
Korea 2017 Review: Biosimilar Advances, R&D Progress Restore Confidence
Keeping Track: Biosimilar Submissions Galore (And An Approval), Bayer Gets An Oncology Approval, KemPharm Resubmits Apadaz NDA
Celltrion's Herceptin Biosimilar One Step Closer To US FDA Approval
Celltrion's Herceptin Biosimilar One Step Closer To US FDA Approval
Keeping Track: Clarus, Agile and Sunovion Look To Bounce Back From CRLs; FDA To Review Rituximab Biosimilar

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099064

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel